Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group ..., Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2008.26.15_suppl.5121.
You can read the full text:
Contributors
The following have contributed to this page
